OpGen, Inc. (OPGN) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
OPGN representa a OpGen, Inc., una empresa del sector Healthcare con un precio de $ (capitalización de mercado 0). La acción obtiene una puntuación de 63/100, una calificación moderada basada en 9 KPI cuantitativos.
Ultimo analisis: 16 mar 2026OpGen, Inc. (OPGN) Resumen de Asistencia Médica y Tuberías
OpGen, Inc. specializes in molecular microbiology solutions, offering diagnostic tools like the Acuitas AMR Gene Panel and Unyvero Platform. These technologies assist clinicians in identifying pathogens and antimicrobial resistance, contributing to improved patient outcomes and infection control within the healthcare sector. The company operates in the United States and internationally.
Tesis de Inversión
OpGen, Inc. presents a notable research candidate within the precision medicine and molecular diagnostics space. The company's focus on combating antimicrobial resistance (AMR) aligns with a growing global health concern. Key value drivers include the increasing adoption of OpGen's Acuitas AMR Gene Panel and Unyvero Platform, driven by the need for rapid and accurate detection of AMR genes and pathogens. The collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC, provides a platform for further research and development in antimicrobial resistance management. However, potential risks include competition from established players in the diagnostics market and the need for continued innovation to maintain a competitive edge. With a market capitalization of $0.25 billion and a profit margin of 76.0%, OpGen demonstrates financial stability and growth potential.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Market capitalization of $0.25 billion indicates the company's current valuation in the market.
- A P/E ratio of 36.43 suggests investors are willing to pay a premium for each dollar of earnings, reflecting growth expectations.
- Profit margin of 76.0% demonstrates strong profitability and efficient operations.
- Gross margin of 98.9% indicates effective cost management in the production of diagnostic solutions.
- Beta of -1.93 suggests the stock price moves inversely to the market, potentially offering diversification benefits.
Competidores y Pares
Fortalezas
- Proprietary ARES Technology Platform for antimicrobial resistance prediction.
- Comprehensive Unyvero Platform for automated molecular diagnostics.
- Collaboration with New York State Department of Health and ILÚM Health Solutions, LLC.
- Strong gross margin of 98.9%.
Debilidades
- Limited market presence compared to larger diagnostic companies.
- Reliance on a small number of key products.
- OTC market listing may limit access to capital.
- Beta of -1.93 indicates high volatility.
Catalizadores
- Ongoing: Increasing adoption of Acuitas AMR Gene Panel due to rising antimicrobial resistance.
- Ongoing: Expansion of ARES Technology Platform capabilities and database.
- Upcoming: Potential new partnerships with healthcare institutions for research and development.
- Upcoming: Possible expansion into new international markets.
- Ongoing: Continued development of novel diagnostic assays for emerging infectious diseases.
Riesgos
- Potential: Competition from established diagnostic companies with greater resources.
- Potential: Regulatory changes affecting the approval and reimbursement of diagnostic tests.
- Potential: Technological advancements rendering existing products obsolete.
- Ongoing: Limited market presence compared to larger competitors.
- Ongoing: OTC market listing may limit access to capital and investor confidence.
Oportunidades de crecimiento
- Expansion of Acuitas AMR Gene Panel adoption: The increasing global threat of antimicrobial resistance (AMR) drives the demand for rapid and accurate diagnostic tools. OpGen's Acuitas AMR Gene Panel offers a solution for detecting and identifying bacterial nucleic acids and genetic determinants of AMR. The market for AMR diagnostics is projected to reach $4.5 billion by 2028, presenting a significant growth opportunity for OpGen. Timeline: Ongoing.
- Leveraging the ARES Technology Platform: OpGen's ARES Technology Platform, with its comprehensive reference database and AI-powered bioinformatics, provides a competitive advantage in antibiotic response prediction. The platform can be expanded to include additional pathogens and resistance genes, broadening its applicability and market reach. The market for AI in drug discovery is expected to reach $2 billion by 2027. Timeline: Ongoing.
- Strategic collaborations and partnerships: Collaborating with healthcare institutions and research organizations can accelerate the development and commercialization of OpGen's diagnostic solutions. The ongoing collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC, serves as a model for future partnerships. Such collaborations can provide access to valuable data, expertise, and funding. Timeline: Ongoing.
- Geographic expansion into international markets: OpGen has the opportunity to expand its market presence beyond the United States by targeting international markets with a high prevalence of infectious diseases and AMR. This expansion can be achieved through strategic partnerships, distribution agreements, and direct sales efforts. The global market for molecular diagnostics is projected to reach $14 billion by 2025. Timeline: 2027-2030.
- Development of novel diagnostic assays: Investing in research and development to create new diagnostic assays for emerging infectious diseases and antimicrobial resistance mechanisms can drive future growth. This includes exploring new technologies such as next-generation sequencing and CRISPR-based diagnostics. The market for novel diagnostic assays is constantly evolving, offering opportunities for innovation and market leadership. Timeline: 2028-2032.
Oportunidades
- Expansion of Acuitas AMR Gene Panel adoption in response to increasing antimicrobial resistance.
- Geographic expansion into international markets.
- Development of novel diagnostic assays for emerging infectious diseases.
- Strategic partnerships with healthcare institutions and research organizations.
Amenazas
- Competition from established diagnostic companies.
- Regulatory changes affecting the approval and reimbursement of diagnostic tests.
- Technological advancements rendering existing products obsolete.
- Economic downturn impacting healthcare spending.
Ventajas competitivas
- Proprietary ARES Technology Platform with extensive antimicrobial resistance database.
- Established relationships with key healthcare institutions and research organizations.
- Unyvero platform provides a comprehensive solution for molecular diagnostics.
- Expertise in molecular microbiology and infectious disease diagnostics.
Acerca de OPGN
OpGen, Inc., established in 2001 and headquartered in Rockville, Maryland, is a precision medicine company dedicated to developing and commercializing molecular microbiology solutions. The company's mission is to combat infectious diseases by providing clinicians with advanced diagnostic tools and information to enhance patient outcomes and reduce the spread of multidrug-resistant microorganisms. OpGen's product portfolio includes the Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test designed for the detection and identification of bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies. This technology enables rapid and accurate identification of resistance genes, aiding in the selection of appropriate antibiotic therapies. Additionally, OpGen offers Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The ARES Technology Platform is another key offering, featuring a comprehensive reference database on antimicrobial resistance using next-generation sequencing technology and artificial intelligence-powered bioinformatics solutions for antibiotic response prediction. The Unyvero Platform, an automated sample-to-answer molecular diagnostics platform, integrates automated sample preparation, analysis, and identification of disease-relevant pathogens and antibiotic resistance markers. OpGen collaborates with the New York State Department of Health and ILÚM Health Solutions, LLC, to develop a research program focused on detecting, tracking, and managing antimicrobial-resistant infections within healthcare institutions.
Qué hacen
- Develop and commercialize molecular microbiology solutions.
- Offer the Acuitas AMR Gene Panel for detecting antimicrobial resistance.
- Provide Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.
- Utilize the ARES Technology Platform for antibiotic response prediction.
- Offer the Unyvero Platform for automated molecular diagnostics.
- Help clinicians with information about life-threatening infections.
- Decrease the spread of infections caused by multidrug-resistant microorganisms.
Modelo de Negocio
- Sales of diagnostic kits and platforms (Acuitas AMR Gene Panel, Unyvero Platform).
- Licensing of ARES Technology Platform and related intellectual property.
- Collaborative research and development agreements with healthcare institutions.
- Service contracts for maintenance and support of diagnostic equipment.
Contexto de la Industria
OpGen operates within the medical diagnostics and research industry, a sector experiencing growth driven by advancements in molecular biology and the increasing prevalence of infectious diseases. The market for antimicrobial resistance (AMR) diagnostics is expanding due to the urgent need for rapid and accurate detection of resistant pathogens. Competition includes established diagnostic companies and emerging players offering innovative solutions. OpGen's focus on precision medicine and its comprehensive product portfolio position it to capitalize on the growing demand for advanced diagnostic tools in healthcare.
Clientes Clave
- Hospitals and healthcare systems.
- Clinical microbiology laboratories.
- Research institutions and universities.
- Public health organizations.
Finanzas
Gráfico e información
Precio de la acción de OpGen, Inc. (OPGN): Price data unavailable
Últimas noticias
-
OpGen, Inc. (OTC: OPGN) Announces Name Change to CapForce Inc.
globenewswire.com · 27 feb 2026
-
PCAOB levies fine on Beckles & Co for late Form AP filings
Yahoo! Finance: OPGN News · 8 dic 2025
-
OpGen Q1 EPS $(0.04) Down From $0.15 YoY
benzinga · 1 oct 2025
-
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga · 11 jun 2024
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para OPGN.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para OPGN.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de OPGN en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Competidores y Pares
Últimas Noticias
OpGen, Inc. (OTC: OPGN) Announces Name Change to CapForce Inc.
PCAOB levies fine on Beckles & Co for late Form AP filings
OpGen Q1 EPS $(0.04) Down From $0.15 YoY
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Liderazgo: Christian-Laurent Benoit Bonte
CEO
Christian-Laurent Benoit Bonte serves as the CEO of OpGen, Inc. He has extensive experience in the healthcare and diagnostics industries, with a background in leading and managing teams. His expertise includes strategic planning, business development, and commercialization of medical technologies. Bonte's previous roles have equipped him with a deep understanding of the challenges and opportunities in the precision medicine space. He is responsible for overseeing the company's overall strategy and operations.
Historial: Under Christian-Laurent Benoit Bonte's leadership, OpGen, Inc. has focused on expanding its product portfolio and strengthening its market position in the molecular microbiology diagnostics sector. Key achievements include the continued development and commercialization of the Acuitas AMR Gene Panel and the Unyvero Platform. Bonte has also overseen strategic collaborations aimed at advancing research and development in antimicrobial resistance management.
Información del mercado OTC de OPGN
The OTC Other tier represents the lowest tier of the OTC market, indicating that OpGen, Inc. may not meet the minimum financial or regulatory requirements for higher tiers like OTCQB or OTCQX. Companies in this tier often have limited reporting requirements and may be subject to greater risks due to less stringent oversight. Trading on the OTC Other tier can result from various factors, including financial distress, regulatory non-compliance, or strategic decisions by the company. Compared to NYSE/NASDAQ, the OTC Other tier offers significantly less transparency and regulatory protection for investors.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited regulatory oversight and disclosure requirements.
- Potential for lower trading volume and liquidity.
- Increased price volatility and wider bid-ask spreads.
- Higher risk of fraud or manipulation compared to listed exchanges.
- Difficulty in obtaining accurate and timely financial information.
- Verify the company's financial statements and regulatory filings.
- Assess the company's management team and their track record.
- Evaluate the company's business model and competitive landscape.
- Review the company's risk factors and potential liabilities.
- Check for any legal or regulatory issues involving the company.
- Monitor the company's news and press releases for updates.
- Consult with a qualified financial advisor before investing.
- Established business operations since 2001.
- Focus on precision medicine and molecular microbiology solutions.
- Collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC.
- Development of proprietary technologies such as the ARES Technology Platform.
- Presence of a CEO with experience in the healthcare and diagnostics industries.
Preguntas Comunes Sobre OPGN
¿Cuáles son los factores clave para evaluar OPGN?
OpGen, Inc. (OPGN) actualmente tiene una puntuación IA de 63/100, indicando puntuación moderada. Fortaleza clave: Proprietary ARES Technology Platform for antimicrobial resistance prediction.. Riesgo principal a monitorear: Potential: Competition from established diagnostic companies with greater resources.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de OPGN?
OPGN actualmente puntúa 63/100 (Grado B) en el MoonshotScore, lo que sugiere calificación moderada. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de OPGN?
Los precios de OPGN se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre OPGN?
La cobertura de analistas para OPGN incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en OPGN?
Las categorías de riesgo para OPGN incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Competition from established diagnostic companies with greater resources.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de OPGN?
La relación P/E para OPGN compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está OPGN sobrevalorada o infravalorada?
Determinar si OpGen, Inc. (OPGN) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de OPGN?
OpGen, Inc. (OPGN) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Information is based on available sources and may be subject to change.
- AI analysis is pending for OPGN stock.